U.S. scientists

a clinical study survey found that women in cancer clinical trials under-represented. According to the survey, women did not receive the experimental drug to obtain a fair opportunity, and the survey authors believe that some men and women may be different treatment effects, their effectiveness has not been fully understood. Findings published in the "cancer" (Cancer) journals.

survey was conducted by the University of Michigan Medical School breast Experts Reshma Jagsi completed leadership. In her research, almost 100% of trial participants are female. However, she suspected other types of cancer clinical trials, whether there is a considerable proportion (that is, with the proportion of women cancer types) of female participants.

Jagsi and colleagues found that hundreds of participants in the study of more than 500,000 samples, 75% are women under-representation of the existence of the phenomenon. Seven kinds of cancer in the study, in which six kinds of women are under-represented. For example, 45% of the lung cancer patients are women, but in the study of lung cancer in an average of only 31% of the female participants.

this under-representation of women is not clear reasons. Jagsi that women of childbearing age may be pregnant during the trial period, which was excluded from trial, but data from this group are equally important. In addition, women with children may be difficult to have time to participate in clinical trials.

Jagsi said that more research is needed to identify the specific cause of the problem and to solve them. A possible solution is the introduction of clinical trials in the compensation mechanism, so look at the cost of children can be sold out.